Law firms are unusually badly served by traditional prospecting, because legal work is not bought on demand. It appears suddenly, attached to an event, and goes to whoever is already trusted or immediately available.
Legal work is downstream of events
Nobody wakes up needing a licensing agreement drafted. They wake up having agreed a deal in principle. Nobody decides to file patents on a Tuesday. They decide because a program produced data worth protecting, or an investor asked what the IP position looks like.
This means the entire art of biotech legal business development is knowing which events create which work, and being visible at the moment they happen.
The events that create legal work
- Financings. Every round means documents, negotiation, and diligence. A first institutional round often means a company is choosing counsel for the first time, which is when relationships are formed for a decade.
- Licensing and partnership deals. The single richest source of transactional work, and increasingly cross-border, which adds complexity most firms are happy to charge for.
- M&A. Acquisitions generate work on both sides, and the losing bidders often need advice too.
- Clinical and regulatory milestones. Positive data means the IP position suddenly matters more, and freedom-to-operate questions become urgent rather than theoretical.
- Patent disputes and expiries in the category. A patent cliff in a therapeutic area creates work across every company touching it.
The first-financing moment is the one that compounds
Most firms chase the large transactional mandates, which is rational but crowded. The overlooked play is the emerging company at its first real financing, when it is choosing counsel with almost no money and enormous long-term stakes.
That client is unglamorous today and potentially enormous in five years, and the relationship is decided in a window most firms are not even watching.
What good outreach looks like
Not a capability statement. A specific, timely observation: you noticed the licensing deal, you understand the cross-border complexity it introduces, you have handled the reversion and diligence terms that tend to cause problems in exactly that structure. That is a conversation. A brochure is not.
Know who to call
Deals closed this week that created legal work with deadlines. The firms that noticed are already having the conversation.
Get Signals for your BD team, $8,000/year for up to 5 seats
Or a single seat, $2,500/year
Every Friday: 15 to 20 tagged signals, a “Who To Call This Week” list of 10 prioritized targets with the trigger and a suggested opening line, and a monthly outreach playbook. Two-week free trial, no commitment. See also the buying signals biotech vendors keep missing.
Frequently asked questions
What events create legal work in biotech?
Financings (every round means documents, negotiation and diligence), licensing and partnership deals (the richest source of transactional work, increasingly cross-border), M&A on both sides of the deal, clinical and regulatory milestones that make the IP position suddenly matter, and patent disputes or expiries in a therapeutic area.
How do biotech law firms find new clients?
By knowing which events create which legal work and being visible when they happen, since legal work is not bought on demand but appears suddenly attached to an event. The overlooked opportunity is the emerging company at its first real financing, when it chooses counsel with little money but enormous long-term stakes.
What is the best business development approach for a law firm?
A specific, timely observation rather than a capability statement. Noticing a licensing deal, understanding the cross-border complexity it introduces, and knowing the reversion and diligence terms that tend to cause problems in that structure earns a conversation. A generic brochure does not.
